新世纪的新型抗菌药物。
Newer antibacterial drugs for a new century.
机构信息
University of Virginia, Department of Medicine, Room 2146 MR4 Bldg, 409 Lane Rd, Charlottesville, VA 22908, USA.
出版信息
Expert Opin Investig Drugs. 2010 Feb;19(2):215-34. doi: 10.1517/13543780903505092.
IMPORTANCE OF THE FIELD
Antibacterial drug discovery and development has slowed considerably in recent years, with novel classes discovered decades ago and regulatory approvals tougher to get. Traditional approaches and the newer genomic mining approaches have not yielded novel classes of antibacterial compounds. Instead, improved analogues of existing classes of antibacterial drugs have been developed by improving potency, minimizing resistance and alleviating toxicity.
AREAS COVERED IN THIS REVIEW
This article is a comprehensive review of newer classes of antibacterial drugs introduced or approved after year 2000.
WHAT THE READER WILL GAIN
It describes their mechanisms of action/resistance, improved analogues, spectrum of activity and clinical trials. It also discusses new compounds in development with novel mechanisms of action, as well as novel unexploited bacterial targets and strategies that may pave the way for combating drug resistance and emerging pathogens in the twenty-first century.
TAKE HOME MESSAGE
The outlook of antibacterial drug discovery, though challenging, may not be insurmountable in the years ahead, with legislation on incentives and funding introduced for developing an antimicrobial discovery program and efforts to conserve antibacterial drug use.
重要性的领域
抗菌药物的发现和开发近年来已经大大放缓，新的类别发现几十年前和监管审批更难获得。传统的方法和新的基因组挖掘方法没有产生新类别的抗菌化合物。相反，通过提高效力、最小化耐药性和减轻毒性，开发了现有抗菌药物类别的改进类似物。
这篇文章综述了 2000 年后推出或批准的新型抗菌药物。
读者将获得
它描述了它们的作用机制/耐药性、改进的类似物、活性谱和临床试验。它还讨论了具有新型作用机制的新型开发中的化合物，以及新的未开发的细菌靶点和策略，这些可能为对抗二十一世纪的耐药性和新兴病原体铺平道路。
抗菌药物发现的前景虽然具有挑战性，但在未来几年可能并非不可逾越，因为已经出台了立法，激励和资助开发抗菌药物发现计划，并努力节约抗菌药物的使用。
Zotero 插件